Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration - PubMed (original) (raw)
Comparative Study
. 2009 Sep;29(8):1067-73.
doi: 10.1097/IAE.0b013e3181b1bb06.
Philip J Rosenfeld, Carmen A Puliafito, William Feuer, Wei Shi, Luma Al-Attar, Sander R Dubovy, Timothy G Murray, Janet L Davis, Wen-Hsiang Lee, Stephen G Schwartz, William E Smiddy, Audina M Berrocal, Harry W Flynn Jr
Affiliations
- PMID: 19696701
- DOI: 10.1097/IAE.0b013e3181b1bb06
Comparative Study
Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration
Kimberly E Stepien et al. Retina. 2009 Sep.
Abstract
Purpose: To compare outcomes after switching from intravitreal bevacizumab (Avastin) to ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration (AMD).
Methods: A retrospective review was performed of patients with neovascular AMD who were switched from treatment with intravitreal bevacizumab to intravitreal ranibizumab once ranibizumab became commercially available. All reviewed patients had at least three bevacizumab injections before being switched to ranibizumab. The treatment outcomes included comparisons of visual acuity and dosing frequency while receiving both drugs.
Results: Eighty-four eyes met the inclusion criteria. Mean baseline visual acuity was 20/100. Mean duration of bevacizumab treatment was 7.1 months followed by 7.3 months with ranibizumab (P = 0.68). Best-obtained visual acuity during treatment was 20/63 with bevacizumab and 20/63 with ranibizumab (P = 0.5). Last mean visual acuity after receiving bevacizumab at the time of the first ranibizumab injection was 20/80. Mean visual acuity at the last ranibizumab follow-up visit was 20/80 (P = 0.49). Mean injection rates per month while receiving bevacizumab and ranibizumab were 0.66 (P = 0.98).
Conclusion: In this subset of patients with neovascular AMD switched from bevacizumab to ranibizumab therapy, there were no apparent differences in visual acuity outcomes or injection rates. Larger prospective studies are under way to directly compare these drugs for the treatment of neovascular AMD.
Similar articles
- Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB. Landa G, et al. Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8. Ophthalmologica. 2009. PMID: 19590252 - A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. Krebs I, et al. Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391. Epub 2013 Jan 3. Br J Ophthalmol. 2013. PMID: 23292928 Clinical Trial. - Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Gupta B, et al. Br J Ophthalmol. 2011 Mar;95(3):386-90. doi: 10.1136/bjo.2010.179499. Epub 2010 Aug 6. Br J Ophthalmol. 2011. PMID: 20693484 - Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM, Noureddine BN, Bashshur ZF. El-Mollayess GM, et al. Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review. - Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Moja L, et al. Cochrane Database Syst Rev. 2014 Sep 15;9(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Cochrane Database Syst Rev. 2014. PMID: 25220133 Free PMC article. Review.
Cited by
- Bevasiranib for the treatment of wet, age-related macular degeneration.
Garba AO, Mousa SA. Garba AO, et al. Ophthalmol Eye Dis. 2010 Dec 19;2:75-83. doi: 10.4137/OED.S4878. Print 2010. Ophthalmol Eye Dis. 2010. PMID: 23861616 Free PMC article. - A Prospective Randomized Comparative Dosing Trial of Ranibizumab In Bevacizumab-Resistant Diabetic Macular Edema: The REACT Study.
Ehlers JP, Wang K, Singh RP, Babiuch AS, Schachat AP, Yuan A, Reese JL, Stiegel L, Srivastava SK. Ehlers JP, et al. Ophthalmol Retina. 2018 Mar;2(3):217-224. doi: 10.1016/j.oret.2017.07.004. Ophthalmol Retina. 2018. PMID: 29527585 Free PMC article. - Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration.
Yamada K, Kimoto K, Kono H, Kubota T. Yamada K, et al. ISRN Ophthalmol. 2011 Dec 21;2011:916789. doi: 10.5402/2011/916789. eCollection 2011. ISRN Ophthalmol. 2011. PMID: 24555120 Free PMC article. - Genetic predictors of response to photodynamictherapy.
Parmeggiani F, Gemmati D, Costagliola C, Semeraro F, Perri P, D'Angelo S, Romano MR, De Nadai K, Sebastiani A, Incorvaia C. Parmeggiani F, et al. Mol Diagn Ther. 2011 Aug 1;15(4):195-210. doi: 10.1007/BF03256411. Mol Diagn Ther. 2011. PMID: 21913742 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous